{"id":165470,"date":"2026-07-23T10:21:30","date_gmt":"2026-07-23T04:51:30","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=165470"},"modified":"2026-07-23T10:21:31","modified_gmt":"2026-07-23T04:51:31","slug":"dr-reddys-share-price-target-clsa-hold-rating","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-target-clsa-hold-rating\/","title":{"rendered":"Dr Reddy&#8217;s Share Price Target Set at Rs 1,240 as CLSA Retains Hold After Q1 Margin Miss on Semaglutide Issues"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Dr Reddy&#8217;s CMP Rs 1,101 (23 Jul, down 6.92%). CLSA hold rating, target Rs 1,240. Q1 margin missed on semaglutide issues. 52W range Rs 1,101 to Rs 1,414.90.<\/em><\/p>\n<p>The <strong>Dr Reddy&#8217;s share price target<\/strong> stands at Rs 1,240 from CLSA, which retained its hold rating even as the stock fell sharply after Dr Reddy&#8217;s Laboratories reported in-line revenue but a margin miss for the first quarter, driven by semaglutide supply issues and higher solvent and freight costs amid the West Asia conflict. Shares dropped nearly 7 percent to around Rs 1,101 on 23 July 2026, a level that touches the stock&#8217;s 52 week low and leaves it well below the CLSA target. The brokerage expects the semaglutide supply issues to stabilise by November 2026 and continues to guide for double digit US base business growth.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=dr-reddys-share-price-target\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-target-clsa-hold-rating\/#Dr_Reddys_Laboratories_Company_Overview\" title=\"Dr Reddy&#8217;s Laboratories Company Overview\">Dr Reddy&#8217;s Laboratories Company Overview<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-target-clsa-hold-rating\/#Why_CLSA_Retained_Its_Hold_Rating_on_Dr_Reddys\" title=\"Why CLSA Retained Its Hold Rating on Dr Reddy&#8217;s\">Why CLSA Retained Its Hold Rating on Dr Reddy&#8217;s<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-target-clsa-hold-rating\/#Q1_Revenue_In_Line_but_Margin_Missed\" title=\"Q1 Revenue In Line but Margin Missed\">Q1 Revenue In Line but Margin Missed<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-target-clsa-hold-rating\/#Semaglutide_Supply_Issues_Expected_to_Stabilise_by_November_2026\" title=\"Semaglutide Supply Issues Expected to Stabilise by November 2026\">Semaglutide Supply Issues Expected to Stabilise by November 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-target-clsa-hold-rating\/#Double_Digit_US_Base_Business_Growth_Guided\" title=\"Double Digit US Base Business Growth Guided\">Double Digit US Base Business Growth Guided<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-target-clsa-hold-rating\/#US_Tariffs_on_Generic_Drugs_Seen_as_Unlikely\" title=\"US Tariffs on Generic Drugs Seen as Unlikely\">US Tariffs on Generic Drugs Seen as Unlikely<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-target-clsa-hold-rating\/#FY27_Estimates_Cut_FY28-29_Forecasts_Trimmed\" title=\"FY27 Estimates Cut, FY28-29 Forecasts Trimmed\">FY27 Estimates Cut, FY28-29 Forecasts Trimmed<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-target-clsa-hold-rating\/#Short_Term_and_12_Month_Price_Outlook\" title=\"Short Term and 12 Month Price Outlook\">Short Term and 12 Month Price Outlook<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-target-clsa-hold-rating\/#Short_Term_Outlook_3_to_6_Months\" title=\"Short Term Outlook 3 to 6 Months\">Short Term Outlook 3 to 6 Months<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-target-clsa-hold-rating\/#12_Month_Analyst_Target_for_2026\" title=\"12 Month Analyst Target for 2026\">12 Month Analyst Target for 2026<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-target-clsa-hold-rating\/#Key_Risks_to_the_Target_Price\" title=\"Key Risks to the Target Price\">Key Risks to the Target Price<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-target-clsa-hold-rating\/#Prolonged_Semaglutide_Supply_Disruption\" title=\"Prolonged Semaglutide Supply Disruption\">Prolonged Semaglutide Supply Disruption<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-target-clsa-hold-rating\/#Elevated_Freight_and_Input_Costs\" title=\"Elevated Freight and Input Costs\">Elevated Freight and Input Costs<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-target-clsa-hold-rating\/#US_Regulatory_and_Pricing_Pressure\" title=\"US Regulatory and Pricing Pressure\">US Regulatory and Pricing Pressure<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-target-clsa-hold-rating\/#How_to_Track_Dr_Reddys_Price_and_Rating_Updates\" title=\"How to Track Dr Reddy&#8217;s Price and Rating Updates\">How to Track Dr Reddy&#8217;s Price and Rating Updates<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-target-clsa-hold-rating\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-target-clsa-hold-rating\/#FAQs_on_Dr_Reddys_Rating_and_Target_Price\" title=\"FAQs on Dr Reddy&#8217;s Rating and Target Price\">FAQs on Dr Reddy&#8217;s Rating and Target Price<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-target-clsa-hold-rating\/#What_target_price_has_CLSA_set_for_Dr_Reddys\" title=\"What target price has CLSA set for Dr Reddy&#8217;s?\">What target price has CLSA set for Dr Reddy&#8217;s?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-target-clsa-hold-rating\/#Why_did_Dr_Reddys_share_price_fall_sharply_today\" title=\"Why did Dr Reddy&#8217;s share price fall sharply today?\">Why did Dr Reddy&#8217;s share price fall sharply today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-target-clsa-hold-rating\/#When_does_CLSA_expect_semaglutide_supply_issues_to_stabilise\" title=\"When does CLSA expect semaglutide supply issues to stabilise?\">When does CLSA expect semaglutide supply issues to stabilise?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-target-clsa-hold-rating\/#What_is_the_52_week_high_and_low_for_Dr_Reddys\" title=\"What is the 52 week high and low for Dr Reddy&#8217;s?\">What is the 52 week high and low for Dr Reddy&#8217;s?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-target-clsa-hold-rating\/#Are_US_tariffs_a_risk_for_Dr_Reddys\" title=\"Are US tariffs a risk for Dr Reddy&#8217;s?\">Are US tariffs a risk for Dr Reddy&#8217;s?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-target-clsa-hold-rating\/#Is_Dr_Reddys_a_buy_at_the_current_price\" title=\"Is Dr Reddy&#8217;s a buy at the current price?\">Is Dr Reddy&#8217;s a buy at the current price?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-target-clsa-hold-rating\/#Where_can_I_track_Dr_Reddys_live_share_price\" title=\"Where can I track Dr Reddy&#8217;s live share price?\">Where can I track Dr Reddy&#8217;s live share price?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Dr_Reddys_Laboratories_Company_Overview\"><\/span><strong>Dr Reddy&#8217;s Laboratories Company Overview<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Parameter<\/th>\n<th>Value<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><a href=\"https:\/\/univest.in\/stocks\/drreddy\/dr-reddy's-laboratories-ltd-share-price-today\">Dr Reddy&#8217;s Laboratories<\/a><\/td>\n<td>NSE: DRREDDY<\/td>\n<\/tr>\n<tr>\n<td>Sector<\/td>\n<td>Pharmaceuticals<\/td>\n<\/tr>\n<tr>\n<td>CMP (23 Jul 2026)<\/td>\n<td>Rs 1,101<\/td>\n<\/tr>\n<tr>\n<td>52 Week High<\/td>\n<td>Rs 1,414.90<\/td>\n<\/tr>\n<tr>\n<td>52 Week Low<\/td>\n<td>Rs 1,101.00<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 98,742 Cr<\/td>\n<\/tr>\n<tr>\n<td>P\/E Ratio<\/td>\n<td>31.02<\/td>\n<\/tr>\n<tr>\n<td>CLSA 12M Target<\/td>\n<td>Rs 1,240<\/td>\n<\/tr>\n<tr>\n<td>Rating<\/td>\n<td>Hold<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Dr Reddy&#8217;s Laboratories is one of India&#8217;s largest pharmaceutical companies with a significant presence in the US generics market, biosimilars and branded formulations. CLSA&#8217;s target of Rs 1,240 implies meaningful upside from the current price of around Rs 1,101, though the hold rating reflects near term caution on margins even as the brokerage sees a path to recovery later in the year.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_CLSA_Retained_Its_Hold_Rating_on_Dr_Reddys\"><\/span><strong>Why CLSA Retained Its Hold Rating on Dr Reddy&#8217;s<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>CLSA pointed to five specific factors shaping its view on the stock following the Q1 results.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Q1_Revenue_In_Line_but_Margin_Missed\"><\/span><strong>Q1 Revenue In Line but Margin Missed<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Dr Reddy&#8217;s Q1 revenue came in broadly in line with estimates, but margins missed expectations due to semaglutide related supply issues along with higher solvent and freight costs stemming from the ongoing West Asia conflict.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Semaglutide_Supply_Issues_Expected_to_Stabilise_by_November_2026\"><\/span><strong>Semaglutide Supply Issues Expected to Stabilise by November 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>CLSA expects the semaglutide supply constraints that weighed on the quarter to stabilise by November 2026, which should support a gradual recovery in margins over the second half of the fiscal year.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Double_Digit_US_Base_Business_Growth_Guided\"><\/span><strong>Double Digit US Base Business Growth Guided<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The company continues to guide for double digit growth in its US base business, with CLSA modelling roughly a 20 percent FY27 EBITDA margin once the semaglutide issues normalise.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"US_Tariffs_on_Generic_Drugs_Seen_as_Unlikely\"><\/span><strong>US Tariffs on Generic Drugs Seen as Unlikely<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>CLSA believes US tariffs on generic pharmaceutical products are unlikely, removing one of the bigger overhangs that had weighed on Indian pharma exporters including Dr Reddy&#8217;s over the past year.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"FY27_Estimates_Cut_FY28-29_Forecasts_Trimmed\"><\/span><strong>FY27 Estimates Cut, FY28-29 Forecasts Trimmed<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Following the Q1 miss, CLSA cut its FY27 revenue and margin estimates for Dr Reddy&#8217;s and trimmed its FY28-29 forecasts, which is the direct driver behind the revised Rs 1,240 target.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/sebi-registered-investment-advisor-india\"><strong>Learn More About Univest, a SEBI Registered Investment Advisor<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Short_Term_and_12_Month_Price_Outlook\"><\/span><strong>Short Term and 12 Month Price Outlook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Short_Term_Outlook_3_to_6_Months\"><\/span><strong>Short Term Outlook 3 to 6 Months<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Having touched its 52 week low of Rs 1,101 on results day, Dr Reddy&#8217;s could see continued volatility in the Rs 1,050 to Rs 1,200 range over the next three to six months as the market digests the extent of the semaglutide related disruption.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"12_Month_Analyst_Target_for_2026\"><\/span><strong>12 Month Analyst Target for 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The 12 month <strong>Dr Reddy&#8217;s share price target<\/strong> from CLSA of Rs 1,240 implies over 12 percent upside from the current price, reflecting confidence in a margin recovery once the semaglutide supply chain normalises later in the year.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_the_Target_Price\"><\/span><strong>Key Risks to the Target Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Prolonged_Semaglutide_Supply_Disruption\"><\/span><strong>Prolonged Semaglutide Supply Disruption<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>If semaglutide supply issues persist beyond November 2026, further downward revisions to earnings estimates and the target price cannot be ruled out.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Elevated_Freight_and_Input_Costs\"><\/span><strong>Elevated Freight and Input Costs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>A prolonged West Asia conflict could keep freight and solvent costs elevated for longer than currently anticipated, pressuring margins across the pharma export business.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"US_Regulatory_and_Pricing_Pressure\"><\/span><strong>US Regulatory and Pricing Pressure<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Generic drug pricing pressure in the US market and FDA related compliance issues remain ongoing risks for Dr Reddy&#8217;s and peers across the broader <a href=\"https:\/\/univest.in\/indices\/nifty-pharma\/nifty-pharma-share-price-today\">Nifty Pharma<\/a> index.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Track_Dr_Reddys_Price_and_Rating_Updates\"><\/span><strong>How to Track Dr Reddy&#8217;s Price and Rating Updates<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Investors tracking analyst calls on Dr Reddy&#8217;s can check live price movement, rating changes and quarterly result updates on the Univest platform. Use the Univest Screener to compare Dr Reddy&#8217;s against other pharma stocks on valuation and earnings growth metrics. Setting alerts around the Rs 1,240 CLSA target and the Rs 1,101 52 week low can help investors react quickly to fresh brokerage commentary.<\/p>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Dr Reddy&#8217;s live price and get daily stock recommendations.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Dr Reddy&#8217;s share price target<\/strong> of Rs 1,240 from CLSA reflects confidence in a gradual margin recovery once semaglutide supply issues stabilise, even though the stock has fallen to a fresh 52 week low following the Q1 miss. Long term investors may find the current valuation attractive relative to the target, though near term volatility is likely. As always, consult a SEBI-registered advisor before making investment decisions.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Dr_Reddys_Rating_and_Target_Price\"><\/span><strong>FAQs on Dr Reddy&#8217;s Rating and Target Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_target_price_has_CLSA_set_for_Dr_Reddys\"><\/span><strong>What target price has CLSA set for Dr Reddy&#8217;s?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> CLSA has set a target price of Rs 1,240 for Dr Reddy&#8217;s Laboratories, along with a hold rating, after the company reported a Q1 margin miss tied to semaglutide supply issues.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_did_Dr_Reddys_share_price_fall_sharply_today\"><\/span><strong>Why did Dr Reddy&#8217;s share price fall sharply today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dr Reddy&#8217;s share price fell nearly 7 percent after the company reported a Q1 margin miss caused by semaglutide supply issues and higher solvent and freight costs amid the West Asia conflict.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"When_does_CLSA_expect_semaglutide_supply_issues_to_stabilise\"><\/span><strong>When does CLSA expect semaglutide supply issues to stabilise?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> CLSA expects the semaglutide supply issues affecting Dr Reddy&#8217;s to stabilise by November 2026, which should support a gradual margin recovery in the second half of the fiscal year.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_52_week_high_and_low_for_Dr_Reddys\"><\/span><strong>What is the 52 week high and low for Dr Reddy&#8217;s?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dr Reddy&#8217;s 52 week high is Rs 1,414.90 and its 52 week low is Rs 1,101, with the stock touching that low on 23 July 2026 after the Q1 results.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Are_US_tariffs_a_risk_for_Dr_Reddys\"><\/span><strong>Are US tariffs a risk for Dr Reddy&#8217;s?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> CLSA believes US tariffs on generic pharmaceutical products are unlikely, which removes one of the bigger overhangs for Dr Reddy&#8217;s and other Indian pharma exporters.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Dr_Reddys_a_buy_at_the_current_price\"><\/span><strong>Is Dr Reddy&#8217;s a buy at the current price?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> CLSA has a hold rating on Dr Reddy&#8217;s with a Rs 1,240 target, implying upside from current levels. Investors should consult a SEBI-registered advisor before making investment decisions.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Where_can_I_track_Dr_Reddys_live_share_price\"><\/span><strong>Where can I track Dr Reddy&#8217;s live share price?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors can track Dr Reddy&#8217;s live share price, analyst ratings and quarterly results on the Univest platform, along with tools like the Univest Screener for peer comparison.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What target price has CLSA set for Dr Reddy's?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"CLSA has set a target price of Rs 1,240 for Dr Reddy's Laboratories, along with a hold rating, after the company reported a Q1 margin miss tied to semaglutide supply issues.\"}},{\"@type\":\"Question\",\"name\":\"Why did Dr Reddy's share price fall sharply today?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Dr Reddy's share price fell nearly 7 percent after the company reported a Q1 margin miss caused by semaglutide supply issues and higher solvent and freight costs amid the West Asia conflict.\"}},{\"@type\":\"Question\",\"name\":\"When does CLSA expect semaglutide supply issues to stabilise?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"CLSA expects the semaglutide supply issues affecting Dr Reddy's to stabilise by November 2026, which should support a gradual margin recovery in the second half of the fiscal year.\"}},{\"@type\":\"Question\",\"name\":\"What is the 52 week high and low for Dr Reddy's?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Dr Reddy's 52 week high is Rs 1,414.90 and its 52 week low is Rs 1,101, with the stock touching that low on 23 July 2026 after the Q1 results.\"}},{\"@type\":\"Question\",\"name\":\"Are US tariffs a risk for Dr Reddy's?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"CLSA believes US tariffs on generic pharmaceutical products are unlikely, which removes one of the bigger overhangs for Dr Reddy's and other Indian pharma exporters.\"}},{\"@type\":\"Question\",\"name\":\"Is Dr Reddy's a buy at the current price?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"CLSA has a hold rating on Dr Reddy's with a Rs 1,240 target, implying upside from current levels. Investors should consult a SEBI-registered advisor before making investment decisions.\"}},{\"@type\":\"Question\",\"name\":\"Where can I track Dr Reddy's live share price?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors can track Dr Reddy's live share price, analyst ratings and quarterly results on the Univest platform, along with tools like the Univest Screener for peer comparison.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dr Reddy&#8217;s share price target is Rs 1,240 as CLSA retains its hold rating after a Q1 margin miss tied to semaglutide supply issues and higher freight costs.<\/p>\n","protected":false},"author":34,"featured_media":165445,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3972],"class_list":["post-165470","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-share-price-target"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1784782296:23"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["78"],"rank_math_title":["Dr Reddy's Share Price Target: CLSA Hold Rs 1,240"],"rank_math_description":["Dr Reddy's share price target is Rs 1,240 as CLSA retains its hold rating after a Q1 margin miss tied to semaglutide supply issues and higher freight costs."],"rank_math_focus_keyword":["Dr Reddy's share price target"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["165445"],"_edit_last":["23"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["29611"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/07\/dr-reddys-share-price-target-clsa-hold-rating-2.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/165470","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=165470"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/165470\/revisions"}],"predecessor-version":[{"id":165548,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/165470\/revisions\/165548"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/165445"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=165470"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=165470"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=165470"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}